Market closed
Carisma Therapeutics Inc./$CARM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Ticker
$CARM
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
46
Website
CARM Metrics
BasicAdvanced
$8.9M
-
-$1.46
2.79
-
Price and volume
Market cap
$8.9M
Beta
2.79
52-week high
$0.49
52-week low
$0.16
Average daily volume
230K
Financial strength
Current ratio
1.484
Quick ratio
1.351
Long term debt to equity
-2.666
Total debt to equity
-8.89
Management effectiveness
Return on assets (TTM)
-62.68%
Return on equity (TTM)
8,783.88%
Valuation
Price to revenue (TTM)
0.45
Price to book
-0.32
Price to tangible book (TTM)
-0.32
Price to free cash flow (TTM)
-0.147
Growth
Revenue change (TTM)
31.59%
Earnings per share change (TTM)
-43.71%
3-year earnings per share growth (CAGR)
-66.15%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Carisma Therapeutics Inc. stock?
Carisma Therapeutics Inc. (CARM) has a market cap of $8.9M as of April 16, 2025.
What is the P/E ratio for Carisma Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Carisma Therapeutics Inc. (CARM) stock is 0 as of April 16, 2025.
Does Carisma Therapeutics Inc. stock pay dividends?
No, Carisma Therapeutics Inc. (CARM) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Carisma Therapeutics Inc. dividend payment date?
Carisma Therapeutics Inc. (CARM) stock does not pay dividends to its shareholders.
What is the beta indicator for Carisma Therapeutics Inc.?
Carisma Therapeutics Inc. (CARM) has a beta rating of 2.79. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.